ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action





















R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet


















Plazomicin EU marketing application is withdrawn: Near zero market value of newly approved antibacterials
Language matters: CRE vs. CPE; SDD vs. I; and MDR, XDR, PDR, UDR vs. DTR
NIAID workshop: What is a robust PK-PD package?
Categories of resistance: MDR, XDR, PDR, UDR, and (new!) DTR
Developing antibiotics for children: There are no easy answers
What does an antibiotic cost to develop? What is it worth? How to afford it?
Mirror Bacteria: An AMR threat of unprecedented magnitude
News from Davos 2020: Some positive signs, but overall a fragile antibiotic market at a tipping point
Developing systemic & inhaled antibiotics for lung infections
FDA: Early endpoints and late endpoints suggest a path to global regulatory convergence (Bart et al.)
Public meeting on the LPAD Pathway: Post-meeting thoughts (wonkish)
New mechanisms for antibiotic reimbursement in the United States: CMS’s IPPS FY2020 Final Rule
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet

The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet